I have a patient presenting with visible hematuria who wants a PSA screening; which ICD‑10‑CM code should be used for the PSA test?

ICD-10-CM Coding for PSA Testing in a Patient with Hematuria

For a patient presenting with visible hematuria who wants PSA screening, use ICD-10-CM code R31.0 (gross hematuria) as the primary diagnosis code for the PSA test, as this represents the clinical indication driving the evaluation.

Clinical Context and Rationale

When a patient presents with blood in the urine and requests PSA testing, the hematuria itself becomes the medical justification for the PSA measurement. This is clinically appropriate because:

• Gross hematuria has a 30-40% association with urologic malignancy 1, making comprehensive urologic evaluation medically necessary
• PSA testing is recommended as part of the hematuria workup in men, particularly when benign prostatic hyperplasia or prostate cancer could be contributing to the bleeding 2
• Prostate cancer prevalence in men with hematuria is 3.0% overall, rising to 5.9% in those with macroscopic hematuria 3, which is substantially higher than general screening populations

Coding Approach

Primary Diagnosis Code:

• R31.0 - Gross hematuria (for visible blood in urine)
• Alternative: R31.1 - Benign essential microscopic hematuria (if microscopic only)
• Alternative: R31.9 - Hematuria, unspecified (if type not documented)

Additional Considerations:

Do NOT use screening codes (Z12.5 for prostate cancer screening) as the primary diagnosis when hematuria is present, because:

• The PSA is being ordered for diagnostic evaluation of a symptom, not for screening 4
• Insurance coverage and medical necessity are established by the presenting symptom (hematuria), not by screening criteria
• Guidelines explicitly state that screening urinalysis should not be used for cancer detection 4

May add secondary codes if clinically relevant:

• Z87.430 - Personal history of urinary tract infections (if applicable)
• N40.0 - Benign prostatic hyperplasia without lower urinary tract symptoms (if BPH suspected)
• Z80.42 - Family history of prostate cancer (if present and relevant)

Clinical Pitfalls to Avoid

1. Don't delay PSA testing - The presence of hematuria is itself an indication for PSA measurement in appropriate-age men 2, particularly since prostate cancer can present with hematuria

2. Don't use anticoagulation as an excuse to skip evaluation - Guidelines explicitly state that anticoagulant therapy does not alter the urologic evaluation of hematuria 1, 4

3. Document the hematuria type clearly - Specify whether gross (visible) or microscopic, as this affects risk stratification and subsequent management intensity 1, 4

4. This patient needs full urologic workup - Beyond just PSA, visible hematuria warrants cystoscopy and imaging (CT urography preferred) 1, 4, so coordinate appropriate referrals

Documentation Tips

In the medical record, document:

• "PSA ordered as part of hematuria evaluation to assess for prostatic pathology as potential source"
• Whether hematuria is gross (visible) or microscopic
• Any associated symptoms (dysuria, frequency, urgency, flank pain)
• Risk factors for urologic malignancy (age >35, male gender, smoking history) 1

This approach ensures proper medical necessity documentation, appropriate reimbursement, and guideline-concordant care for a patient with a potentially serious urologic symptom.